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Abstract 
Leishmaniasis is one of the most dreadful diseases as a leading cause of death in most of the 
developed countries. In the given study molecular docking study was performed on the library of 
coumarin analogues as anti-leishmaniasis agents. Total 300 coumarins analogues were taken from 
Pubmed and were studied using a molecular docking study on trypanothione reductase from 
Leishmania infantum(PDB code: 2JK6 and 2P18) and Leishmania mexicana (PDB code: 3PP7). 
Molecular docking result revealed that most active compound COU-130 and COU-220 bind to the 
active site of the protein with amino acids present in the various proteins. In PDB 2JK6 the active 
compound binds to the amino acid thr-51 and ser-14 were binding to the active site, and in PDB 3PP7 
the active compound binds amino acid thr-26 and in PDB 2P18 the active compound binds to the 
amino acid phe-219 and try-212. Further in vitro and in vivo study of selected coumarin analogues 
can be studied for their therapeutic potential in treating leishmaniasis. 
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Introduction 
Leishmaniasis is one of the most dreadful diseases and is a leading cause of deaths in developing 
countries
[1]
. Compared to chemical synthesis, plant derived natural products represents an attractive 
source of biologically active agents since they are natural and are economic to afford. Objective of the 
given work is to identify more potent and highly effective novel compound for the treatment of 
leishmaniasis, which could be further used as a therapeutic agent in treating leishmaniasis. 
Materials and Methods 
Molecular Docking: Molecular docking was performed by Molegro Virtual Docker 6.0, molecular 
docking was employed to identify the best geometry of ligand-receptor complex. In the present study 
300 coumarin analogue were docked on the active site of three different [PDB code 2JK6
[2]
; 3PP7
[3]
; 
2P18
[4]
] retrieved from protein data bank. 
Result and Discussion 
Molecular docking results revealed that most active compound COU-130 and COU-220 binds to the 
active site of the protein [PDB code: 2JK6, 2P18 and 3PP7]. In PDB 2JK6 the active compound binds 
to the amino acid thr-51 and ser-14 were binding to the active site Fig 1a, and in PDB 3PP7 the active 
compound binds amino acid thr-26 Fig. 1b and in PDB 2P18 the active compound binds to the amino 
acid phe-219 and try-212 Fig. 1c.  
The Molecular docking  score was obtained as follows. 
 
 
 
  
Table 1a [PDB code: 2JK6] 
Compound Name Moldock score Rerank score 
COU-130 -172.948 -122.454 
 
Table 1b [ PDB code: 3PP7] 
Compound name Moldock score Rerank score 
COU-130 -127.413 -100.061 
 
Table 1c [PDB code: 2P18] 
Compound Name Moldock score Rerank score 
COU-220 -116.818 84.5171 
 
 
Fig.1a       Fig.1b     Fig. 1c 
The crystal structure superposition of the structure and the final conformations suggests that the 
ligands were docked into the same site of binding and have a close resemblance to the pose of the 
ligand which was present in the crystal structure. 
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Conclusion 
The given study is valuable, inexpensive and important for further in vitro and in vivo studies.  
Selected coumarins analogues can be studied for their therapeutic potential in treating Leishmaniasis.                   
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